Australian investors and other backers worldwide have pumped $52 million into GI Dynamics. The company will use the funding to wrap up a 500-participant pivotal study of EndoBarrier, a device already approved in certain countries in Europe as well as Chile and Australia for use in treating patients with obesity and type 2 diabetes.

Related Summaries